Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引：14
|
作者：
Chanthavanich, Pornthep [1 ]
Limkittikul, Kriengsak [1 ]
Sirivichayakul, Chukiat [1 ]
Chokejindachai, Watcharee [1 ]
Hattasingh, Weerawan [1 ]
Pengsaa, Krisana [1 ]
Surangsrirat, Surachai [2 ]
Srisuwannaporn, Termsang [2 ]
Kaewma, Benjawan [2 ]
Yoksan, Sutee [3 ]
Jun, Gao [4 ]
Zhumu, Bai [4 ]
机构：
[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand
[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand
[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand
[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;
D O I：
10.1080/21645515.2017.1414763
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.
引用
收藏
页码：900 / 905
页数：6
相关论文
共 50 条
  • [31] Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004
    Mitchell, DK
    Ruben, FL
    Gravenstein, S
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (10) : 925 - 927
  • [32] Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children
    López, EL
    Xifró, MD
    Torrado, LE
    De Rosa, MF
    Gómez, R
    Dumas, R
    Wood, SC
    Contrini, MP
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (01) : 48 - 52
  • [33] COMPARATIVE IMMUNOGENICITY IN CHILDREN OF MAMMALIAN CELL-DERIVED RECOMBINANT HEPATITIS-B VACCINE AND PLASMA-DERIVED HEPATITIS-B VACCINE
    COURSAGET, P
    BRINGER, L
    SARR, G
    BOURDIL, C
    FRITZELL, B
    BLONDEAU, C
    YVONNET, B
    CHIRON, JP
    JEANNEE, E
    GUINDO, S
    DIOPMAR, I
    VACCINE, 1992, 10 (06) : 379 - 382
  • [34] Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study
    Cramer, Jakob P.
    Dubischar, Katrin
    Eder, Susanne
    Burchard, Gerd D.
    Jelinek, Tomas
    Jilma, Bernd
    Kollaritsch, Herwig
    Reisinger, Emil
    Westritschnig, Kerstin
    VACCINE, 2016, 34 (38) : 4579 - 4585
  • [35] Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
    Tambyah, Paul A.
    Wilder-Smith, Annelies
    Pavlova, Borislava G.
    Barrett, P. Noel
    Oh, Helen M. L.
    Hui, David S.
    Yuen, Kwok-Yung
    Fritsch, Sandor
    Aichinger, Gerald
    Loew-Baselli, Alexandra
    van der Velden, Maikel
    Maritsch, Friedrich
    Kistner, Otfried
    Ehrlich, Hartmut J.
    VACCINE, 2012, 30 (02) : 329 - 335
  • [36] Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial
    Liu, Xiaoyu
    Yang, Wanqi
    Zhang, Chao
    Wu, Heng
    Wang, Ruize
    Ding, Qiang
    Hu, Yan
    Xiong, Yongli
    Zhang, Shaobai
    Wang, Lin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 5348 - 5354
  • [37] A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea
    Kim, Dong Soo
    Houillon, Guy
    Jang, Gwang Cheon
    Cha, Sung-Ho
    Choi, Soo-Han
    Lee, Jin
    Kim, Hwang Min
    Kim, Ji Hong
    Kang, Jin Han
    Kim, Jong-Hyun
    Kim, Ki Hwan
    Kim, Hee Soo
    Bang, Joon
    Naimi, Zulaikha
    Bosch-Castells, Valerie
    Boaz, Mark
    Bouckenooghe, Alain
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (09) : 2656 - 2663
  • [38] Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up
    Dubischar-Kastner, Katrin
    Kaltenboeck, Astrid
    Klingler, Anton
    Jilma, Bernd
    Schuller, Elisabeth
    VACCINE, 2010, 28 (39) : 6463 - 6469
  • [39] Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study
    Vesikari, Timo
    Nauta, Jos
    Lapini, Giulia
    Montomoli, Emanuele
    van de Witte, Serge
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 : 29 - 37
  • [40] The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
    Kwon, Hyo Jin
    Lee, Soo Young
    Kim, Ki Hwan
    Kim, Dong Soo
    Cha, Sung Ho
    Jo, Dae Sun
    Kang, Jin Han
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (05) : 612 - 616
12345